Serum antibodies to blood group A predict survival on PROSTVAC-VF.

ABSTRACT:

Purpose

There is evidence that therapeutic cancer vaccines can lengthen survival for some patients with cancer, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy.

Experimental design

This retrospective study included 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. A glycan microarray was used to profile prevaccination antiglycan antibody populations in sera as potential biomarkers for PROSTVAC-VF. The screen for predictive biomarkers identified antiglycan antibodies that consistently stratified subjects into groups with different Kaplan-Mei

SUBMITTER: Campbell CT 

PROVIDER: S-EPMC3594414 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature